Position in MEDP
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,572,613
+$753,130 QoQ
Shares Held
7,440
+48.2% QoQ
Ownership
0.026%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MEDP Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Verition Fund Management LLC holds $55,485,979 across 17 Diagnostics & Research names. MEDP ranks #6 (6.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
21,462 | $10,549,216 | |
| 2 | SHC |
Sotera Health Co
|
425,499 | $6,101,655 | |
| 3 | A |
Agilent Technologies, Inc.
|
50,510 | $5,757,129 | |
| 4 | WAT |
Waters Corp /De/
|
19,028 | $5,666,538 | |
| 5 | ICLR |
Icon PLC
|
42,343 | $4,685,676 | |
| 6 | MEDP |
Medpace Holdings, Inc.
This page
|
7,440 | $3,572,613 | |
| 7 | RDNT |
RadNet, Inc.
|
55,691 | $3,112,569 | |
| 8 | CRL |
Charles River Laboratories International, Inc.
|
17,989 | $3,103,102 |
All Filings in MEDP
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,572,613 | 7,440 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,819,483 | 5,020 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $8,368,982 | 16,277 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,811,913 | 5,773 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,038,688 | 3,409 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $623,595 | 1,877 | Shares | Sole | 2025-02-14 | |
| 2024-06-30 | $937,370 | 2,276 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $360,097 | 891 | Shares | Sole | 2024-05-14 | |
| 2023-06-30 | $1,545,493 | 6,435 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $355,790 | 1,892 | Shares | Sole | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||